Diagnosis and treatment progress of upper eyelid abnormalities in thyroid-eye disease.

Authors

Cheng Gai, Bing Wang

Published in

Frontiers in endocrinology. Volume 17. Pages 1860864. Epub Jul 13, 2026.

Abstract

Thyroid eye disease (TED) is the most common orbital disorder among adults. Among its many clinical features, upper eyelid abnormalities-namely, retraction, lid lag, and swelling-frequently cause functional and cosmetic problems. This article reviews current knowledge on diagnosing and treating these abnormalities. We examine a range of options, from basic supportive care and local injections (botulinum toxin A, hyaluronic acid, and triamcinolone) to systemic drugs (corticosteroids, Teprotumumab, and alpha-1 antagonists) and surgery (levator recession, blepharotomy, and orbital decompression). Recent data suggest that IGF-1 receptor antagonists, especially Teprotumumab, can substantially reduce eyelid retraction and proptosis with a better safety profile than traditional glucocorticoids. Nevertheless, important questions remain: few head-to-head trials exist, the optimal timing for biologics versus surgery is unclear, and treatment needs to be individualized. Future studies should integrate artificial intelligence for quantitative eyelid assessment and promote multidisciplinary care. This review offers a practical framework for clinicians and outlines their research priorities.

PMID:
42516758
Bibliographic data and abstract were imported from PubMed on 28 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.